NOTICE OF ANNUAL GENERAL MEETING

(1) 2025 REPORT OF THE BOARD OF DIRECTORS (2) 2025 REPORT OF THE BOARD OF SUPERVISORS (3) 2025 ANNUAL REPORT (4) RE-APPOINTMENT OF AUDITOR (5) REMUNERATION OF DIRECTORS (6) REMUNERATION OF SUPERVISORS (7) GENERAL MANDATE TO ISSUE ADDITIONAL SHARES (8) GEN

Boan Biotech’s Boluojia® Newly Approved in China for Treating Bone Metastases from Solid Tumors and Multiple Myeloma

Boan Biotech announced today that China’s National Medical Products Administration (NMPA) has approved the supplemental application for Boluojia® (denosumab injection 120 mg) for the treatment o...

VOLUNTARY ANNOUNCEMENT BOLUOJIA (DENOSUMAB INJECTION) NEWLY APPROVED IN CHINA FOR TREATING BONE METASTASES FROM SOLID TUMORS AND MULTIPLE MYELOMA

VOLUNTARY ANNOUNCEMENT ON-MARKET SHARE REPURCHASE

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026

2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT

ANNUAL REPORT 2025

ANNUAL REPORT 2025

PROPOSED ADOPTION OF RESTRICTED SHARE UNIT INCENTIVE SCHEME